

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbsilpa.com, Web: www.vbsilpa.com
CIN: L85110KA1987PLC008739

June 29, 2023

Corporate relationship Department,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India, Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (E),
Mumbai 400051

Dear Sir/Madam,

Sub: Intimation U/R of the SEBI (LODR) Regulations – Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE -530549

Shilpa Medicare Limited Launches Lenvatinib Capsules (12mg, 18 mg and 24 mg) in India under the brand name Lenshil[®]

This is to inform you that the company has received approval from CDSCO, New Delhi for manufacturing and sale of Lenvatinib Capsules, 12, 18 and 24 mg in India. Shilpa will commercialize the product under the brand name **Lenshil[®]**. Lenshil[®] 12 mg and Lenshil[®] 18 mg will be launched immediately followed by Lenshil[®] 24 mg.

Shilpa Medicare Limited is the first company to receive approval for Lenvatinib Capsules, 12, 18 and 24 mg **in India**. The company is already marketing the 4 mg and 10 mg strengths. **The first time launch** of this new drug in India will offer great benefits in terms of flexibility of dosage and patient convenience in specific cancer indications. For treating hepatocellular carcinoma, the recommended dosage is 12 mg orally once daily for patients greater than or equal to 60 kg. For treating Renal Cell Carcinoma (RCC) the recommended dosage is 18 mg orally once daily and for Differentiated Thyroid Cancer the recommended daily dose of Lenvatinib is 24 mg once daily.

Shilpa's first-in-India - Lenshil[®] 12 mg, Lenshil[®] 18 mg and Lenshil[®] 24 mg will allow physicians and patients to administer only one capsule instead of three capsules of the currently available 4 mg and 10 mg strengths. Lenshil[®] is a bioequivalent and pharmaceutically equivalent version of the brand product Lenvima[®] of Eisai, USA.

Shilpa Medicare Limited, is a research driven, global, integrated pharmaceutical company, headquartered in Raichur, Karnataka, India and is engaged in research and development, manufacturing and sale of oncology drugs and formulations.

With Regards,

For Shilpa Medicare Limited

Ritu Tiwary

Company Secretary & Compliance Officer